Zhang et al. [14] applied this novel technology identified CD133 and PD-L1 as diagnostic biomarkers for colorectal cancer (CRC) with early-stage, while they identified the HER2 as an advanced biomarker for CRC. This evidence concerns the gene PROM1 and colorectal cancer.